Eric Lefkofsky, Founder and CEO at Tempus, shared on LinkedIn:
“It’s exciting to see the FDA’s evolved thinking on how AI might play a meaningful role in clinical care: discussion paper. This along with CMS’s recent decision in June to add a new category for Software as a Medical Service sets the stage for companies like Tempus AI, who have been preparing for this sea change for over a decade.”
You might be interested in:
Tempus AI to Acquire Personalis in $1.5 Billion Deal, Deepening Its Foothold in Cancer Monitoring
